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Abstract
This quality improvement project was inspired as an answer to a problem that intellectual disability teams have been struggling to manage
whilst caring for people with epilepsy (PWE). The issue was that despite guidance to discuss the possibility of sudden unexpected death in
epilepsy (SUDEP) be discussed with a newly diagnosed PWE this is rarely done. Additionally when, how, and what to discuss about SUDEP
and reduce its risk is arbitrary, non-person centred, and with no structured evidence.
Prior to initiating changes a discussion of SUDEP was recorded in just 10% of PWE. We introduced a check-list to help identify risk factors for
SUDEP. We then modified the check-list, and then used it via telehealth, a way of contacting patients and their carers over the phone using
the check-list approach. Following interventions, discussions of SUDEP are now recorded in 80% of PWE. Feedback from patients, carers and
primary and secondary care professionals has been positive.
We are now developing an app so that patients and carers can monitor their own risk factors, thus empowering them and increasing their
knowledge and awareness of SUDEP.
Problem
UK has 600,000 people with epilepsy (PWE), 30% being treatment
resistant with a 42% sudden unexpected death in epilepsy
(SUDEP) lifetime risk. Sudden death is 20 times higher in PWE to
general population. Epilepsy is the 5th highest cause of life-years
lost. Forty-two percent of deaths are considered avoidable.[1]
Epilepsy NICE guidelines 2004 and 2012 [2] recommend discussion
of SUDEP with newly diagnosed PWE. This is rarely followed and
until recently only 4% PWE had a recorded SUDEP discussion.[3]
In their current publication of the NHS Outcomes Framework, the
Government prioritizes the prevention of amenable mortality,
making it a core focus for NHS services. Epilepsy mortality features
in new NICE Standards as well as NICE Clinical Guidelines. The
public health burden of SUDEP alone is estimated as second only
to stroke among neurological conditions.[4]
However, the dilemma remains of when, how, and what to discuss
about SUDEP. Meaningful structuring of its risk is arbitrary, non-
person centered with no evidenced mechanism.
At the two epilepsy services locally in Cornwall for people with
intellectual disability (ID), as well as in the general population, the
recorded discussion of SUDEP was less than 10%.
In Cornwall, the local community was motivated by the sudden
unexpected death of a young nurse. Kt’s Fund commissioned
SUDEP Action to work in partnership with local researchers and
epilepsy clinicians of Cornwall. A strong local partnership of
stakeholders with input from national experts including specialists,
general practitioners (GPs) and the HM Coroner has embraced this
project. All PDSA cycles have involved local and national epilepsy
experts, service users, national epilepsy charities, and GPs.
Background
There is a substantial body of work on SUDEP.[5, 6] While no
definitive mechanism or factors have been categorically identified,
research has shown that there are various factors which can
influence risk of an adverse outcome. A detailed literature review
was done to identify the nature of the problem and the available
evidence. It concluded that evidence of risk factors exist but that
this has not been brought together in a systemic manner to help
patients, and that clinicians have a person centred discussion of
individual risk.
In clinical practice the lack of any tools to support risk management
is of concern. Risk management has been highlighted as vitally
important to reducing avoidable epilepsy-related deaths, both in
research and reporting, but also via prevention of future death
reports and fatal accident inquiries held by those investigating
sudden and unexpected deaths
(www.sudep.org/epilepsy-deaths-reports).
A central theme of all these reports is a lack of awareness or
underestimation of risk. In some places the idea that seizures are
benign persists, a myth that was widespread in the 1990’s. SUDEP
occurs today in the context of the reduction of GPs Quality and
Outcomes Framework (QOF) payments for epilepsy and in many
areas pressures in hospitals to discharge patients early [7] all
impacting on the care for those with epilepsy.
Baseline measurement
In 2010 a specialist epilepsy service of 350 complex PWE and ID
were reviewed for any discussion on SUDEP. Less than 10% had a
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recorded discussion of SUDEP. There was less than 1% of a
recorded discussion of a person centred discussion of SUDEP
looking into specific patient risk and characteristics in order to
empower patents and their family to take safety measures. People
with epilepsy want information on risk.[8, 9] While there is some
evidence that communication of risk is improving, it is very slow.[10]
Design
The team involves NHS Trusts, universities, primary and secondary
care, international epilepsy experts, local specialists, GPs, national
epilepsy charities, and service users.
The problem required a solution which was evidenced based,
simple to use in a clinical setting, could be easily re-adopted across
a range of settings and practices, and would be easy to
communicate with patients/carers with clear outcomes for change. It
also needed to be modifiable to change and lend itself to a range of
applications.
A detailed literature review was undertaken to determine SUDEP
contributory risk factors. A total of 18 factors were identified of
which 11 were deemed modifiable and having the potential to
influence the SUDEP risk. A SUDEP safety checklist [5, 6] to help
communicate and quantify risk was postulated taking account the
epilepsy factors (duration of epilepsy, seizure increase in frequency
and intensity), psychological factors (depression, anxiety), social
factors (alcohol intake, compliance, nocturnal surveillance) and
biological factors (sleep disturbances, recent medication changes,
co-morbid physical health diagnosis etc). This was populated onto
an A4 checklist. A safety checklist supports the goal of patient
safety by focusing on the modifiable factors and guiding treatment.
It can also be a tool to open a person centred discussion with
patients that outlines how individual behaviours could impact on risk
(for example, lack of compliance, alcohol misuse, etc) and to help
engagement between doctors and patients.
Strategy
PDSA cycle 1: The SUDEP safety checklist developed from
literature review was used as the data collecting tool for a
retrospective study incidentally the largest epidemiological study for
SUDEP in England.[11] The study was completed in Cornwall with
the coroner and looked at the risk factors of all deaths linked to
epilepsy 2003 -2012, helping to confirm and improve aspects of the
tool to make it more patient focused. It helped confirm risk factors
for worsening of epilepsy control and SUDEP. It additionally
highlighted the presence of modifiable risk factors identifiable three
to six months prior to the demise of the individual, which when not
corrected had a potential cumulative effect on the individual’s
seizure control and risk.
The study found that only 20% of people with epilepsy who died
suddenly appeared to have been contact with specialist services in
the previous year. For those with tonic-clonic seizures (a risk factor
for SUDEP), in about 90% of the deaths there was a noted
increased in seizure frequency three to six months before their
death. One half had a record of alcohol misuse, and a quarter had
been taking drugs to treat depression or anxiety.
This cycle highlighted the identifiable presence of modifiable risk
factors three to six months prior to demise, which going uncorrected
had a potential cumulative effect on seizure control and risk.
PDSA cycle 2: The checklist has now been in use for two years as
routine practice in epilepsy clinics in Cornwall and Plymouth, with
feedback from over 200 PWE/carers. Ninety eight percent
responded positively, and 2% were neutral. Feedback was
reviewed and assimilated. Those who scored highly said it would
make them think about the issues they could address. Those with
low scores, and who were previously aware of SUDEP, said it was
a relief to be told. Interestingly this challenges the popular
preconception that it would upset patients to discuss SUDEP. It
appears a structured approach pays dividends in focusing
individuals on items within their locus of control.
Clinical use of the safety checklist with the "at risk population" and
subsequent feedback from PWE and their carers showed 98%
positive and 2% neutral feedback for the quality of consultation
provided using the checklist. High scorers on the checklist said it
made them think of issues to address and modify esp. with life style
choices.
In the last two years 80% of PWE accessing Cornwall epilepsy
services have had their SUDEP risk assessed and recorded. Prior
to this locally only 8% of patients were assessed in this systematic
way and the percentage is much lower in other areas.
PDSA cycle 3: A telehealth pilot of proactive checks using the
checklist was implemented on 15 high risk patients defined as
having treatment resistant seizures for over 10 years but stable in
the community from an eligible 90 patients with epilepsy from a
large GP surgery having a catchment population of 16,000. Every
three months a telehealth nurse calls up the registered patients and
runs the checklist with them. All results are then communicated to
the GP in a timely way. Telehealth services in what was considered
a stable "at risk" population led in practice to 17% receiving several
interventions in the last one year that would not have happened
without the tool. Clinicians across primary and secondary care have
reported that this is working well as an intervention to raise
awareness and improve the management of high risk patients
proving a useful system for clinicians and an improvement on
previous clinical practice.
PDSA cycle 4: We are developing a mobile app "EpsMon" that
incorporates the risk factors identified and tested in the previous
PDSA cycles with a view to empowering service users to monitor
their own risk. It is being done in association with Plymouth
University and SUDEP Action UK, a national charity.
Results
There have been zero sudden unexpected death in epilepsy in the
ID epilepsy service in the last five years. This is from data at the
coroners where every death that is epilepsy linked is now
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examined. In the last two years, 80% of PWE accessing Cornwall
epilepsy services have had their SUDEP risk assessed compared
with 8% in the past. Clinical use showed the feedback as 98%
positive and 2% neutral. High scorers said it made them think of
issues to address.
Telehealth services offered to 15 PWE led to 14 consenting and
requesting to take it up. Routine checks using the service and the
safety checklist in a stable "at risk" population led to 17% receiving
several interventions that would not have happened without the
tool. Both the primary and secondary care doctors felt the checklist
raised awareness and management of high risk patients.
Our results also challenge the popular preconception that
discussing SUDEP would upset patients. A structured approach
pays dividends in focusing individuals on items in their locus of
control. There is developing evidence of improving safety by
indicators of A/E admissions, clinicians, patients and carer feedback
and SUDEP reduction.
Lessons and limitations
The tool is used by epilepsy clinicians across Cornwall UK,
dispersed to other parts of the UK (Plymouth, Birmingham, etc) and
centres in New Zealand, France, Canada, Brazil, Netherlands, etc.
Publications were in the top five downloaded for the journal Seizure
(Impact Factor 2) in the first three months of publication. The safety
checklist has been populated into a Microsoft Excel® spreadsheet.
An initial risk assessment is conducted with the patient during their
first consultation in order to gain an individual baseline SUDEP risk
rating for the patient. When the patient returns for a follow up or
there is a change of treatment/medication then the risk assessment
will be undertaken again. Epilepsy clinicians have found the tool
simple and quick to use (five minutes in clinic). The assessment is
stored in the patient’s medical notes. When risk is increasing
clinicians can intervene to mitigate. Costs in time and resources are
negligible.
Limitations: Changing cultural stereotypes takes a generation.
Awareness of the public burden of SUDEP has improved in recent
years, but has not been translated into communications with
patients. While the SUDEP checklist is being used in many places
across the UK and internationally it is still not in the common
professional/clinical psyche of the practicing epilepsy clinician. Till
date there is ongoing debate of the need and value to inform PWE
of SUDEP.[12] However, our work challenges this view.
Conclusion
From governance perspective, knowing how people feel about risk
is essential for effective regulation. In this information rich world
people increasingly want to know more about their medical
conditions, treatment, and their risks. This five minute risk
assessment checklist serves to inform PWE about their risk factors
and how some lifestyle changes; for example, medication
compliance and surveillance at night can have a positive impact on
mitigating their individual risk of SUDEP. The evidence based
checklist identifying the major risk factors helps both clinicians and
patients to focus on minimizing certain risk factors and promotes
safety by focusing on the modifiable factors and guides treatment. It
is a tool to open person centered discussion and to outline how
individual behaviors could impact on risk. It provides documentary
evidence for the clinicians on the impact the treatment plan over a
period of time and demonstrates effective clinical governance while
enhancing patient safety.[13]
While there is no proven intervention or national surveillance of
epilepsy mortality, the safety checklist is a simple and practical tool
that can be used to demonstrate effective clinical and corporate
governance while enhancing patient safety. It can also help give
some assurance to bereaved families that every effort was made to
reduce risk and prevent a fatality.
It also lends itself to a variety of templates such as paper A4
sheets, Excel format to monitor risk longitudinally, telehealth
services and is being developed into a patient self-monitoring
mobile app, EpsMon.
While the safety checklist was developed for SUDEP risk, factors
such as non-adherence, depression, and substance misuse appear
to closely overlap with the findings on risk from literature on all
causes of epilepsy mortality.[14-16] The safety checklist, updated to
take account of latest evidence, will be available in the spring of
2015.
The updated checklist is available from www.sudep.org. The
Checklist risk factors will be reviewed every two years by a
committee of international experts in epilepsy brought together by
SUDEP Action who would revisit the relevance of each risk factor
as per current evidence and if appropriate recommend removal of
out dated factors or addition of new relevant factors.
A peer reviewed editorial discussing the application of technology
for PWE where in the SUDEP Checklist project utility is discussed
has been accepted in the British Journal of General Practice.[17]
The release of EpsMon would raise awareness of epilepsy risk
among people with epilepsy who would then approach their health
professionals to help them assess and understand risk. In addition
the SUDEP checklist has been discussed to be part of the national
commissioning tool kit for epilepsy to evidence safety. Promotional
events and peer reviewed presentations at epilepsy conferences
have been planned or conducted to increase awareness nationally
and internationally.
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